You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復旦張江(01349.HK)董事會同意附屬公司進行二期醫藥生產基地項目建設
格隆匯 08-11 17:24

格隆匯8月11日丨復旦張江(01349.HK)公佈,公司附屬公司泰州復旦張江藥業有限公司("泰州復旦張江")作為集團重要的生產基地,為滿足集團後續研發項目的產業化進程及推進現有研發管線申報進度,根據集團戰略規劃和經營發展需要,經公司董事會於2021年8月11日會議審議,批准泰州復旦張江在其現有廠房之相鄰土地上進行二期醫藥生產基地項目建設。該項目包括建設總建築面積約42,000平方米的抗體偶聯藥物車間、固體制劑車間、注射劑車間以及與之配套的辦公、研發、質檢、倉儲、環保等輔助設施。該項目投資總額為人民幣6億元(其中包含代價為1,265萬元的土地使用權競拍款),資金來源全部為自有資金。

該項目的實施將有助於進一步推進公司的業務發展,優化公司產業佈局,有利於提升公司研發創新能力和市場競爭力,實現公司的可持續發展,符合公司的戰略發展規劃和長遠發展目標。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account